Can This Number Push ISRG Stock Higher?
Intuitive Surgical (ISRG) shares fell 10.4% in the past year, while the S&P 500 returned 16.5%. Much of the market has focused on moderating U.S. procedure growth. The more telling number is 144 trade-ins in fiscal Q2 2026, up from 83 a year earlier. Most came from customers moving to the new da Vinci 5 robot. Those trade-ins matter most if upgrades continue and each surgery also earns more. Is that number a blip, or are customers still trading up?
Customers Traded Up Faster Than A Year Earlier
Management said US customers drove most of those trade-ins. The new model also led new placements, at 246 of the 468 systems placed in the quarter.
Buyers also paid more per system. The average purchased da Vinci system sold for $1.6 million, against $1.5 million a year earlier. Management tied that rise to more da Vinci 5 and dual console systems in the mix.
Most of the installed base has not moved yet. Just over 1,700 of the new robots are installed, out of almost 13,000 systems worldwide. That is roughly one in eight. Management said the previous upgrade cycle took about seven years to reach peak trade-ins, and called that a reference only.
Systems revenue brought in $685 million of the quarter’s $2.89 billion in revenue. That makes them the smaller part of the business, so the upgrade pays more if each surgery also earns more.
Does Each Surgery Earn More?
On average, each surgery earns a little more. Revenue from instruments and accessories, the tools used in each operation, rose to about $1.83 thousand per da Vinci procedure. That compares with $1.8 thousand a year earlier. Management credited more procedures on the da Vinci 5 and the SP system.
The worry about Intuitive is surgery volume. Management said US growth moderated in fiscal Q2 2026, mostly in procedures patients can put off. Some customers linked that to changes in patient coverage and premiums. US da Vinci bariatric cases also fell at a high single-digit rate as use of weight-loss drugs rose.
Total procedures still grew 16% in the quarter. Management also kept its full-year da Vinci procedure growth range of 13.5% to 15.5%. The upgrades do not bring deferred patients back, though. The shift to da Vinci 5 and SP procedures lifts instrument revenue per surgery only slightly.
The share price is 41.7 times the company’s profit per share over the past year. That multiple is near the low end of its range over ten years. The price appears to reflect the slowdown more than the upgrades. That small gain per surgery is what a planned cut in customers’ instrument costs could give back.
Will Cheaper Instruments Erase That Gain?
The trade-in count cannot answer that, because the pricing is not set yet. From the first half of 2027, management expects some instruments to last for more uses. Management said the change will lower customers’ cost per use, with the lower cost aimed at high-volume procedures for non-cancer conditions.
Management is still finalizing that pricing and will put a number on it at the next earnings call. On the fiscal Q2 2026 call, management declined to say whether instrument revenue per case would go flat. Management said it balances two goals, growth and profitability.
So far the upgrades look solid, while the per-surgery gain is thin. Management plans to quantify that pricing on the fiscal Q3 2026 call. The answer shows how much of that gain could survive. If instrument revenue per surgery remains flat in 2027, system upgrades would primarily drive top-line expansion through hardware placements rather than recurring per-procedure instrument growth.
How To Act On ISRG?
